---
input_text: 'Growth hormone treatment improves growth and clinical status in prepubertal
  children with cystic fibrosis: results of a multicenter randomized controlled trial.
  CONTEXT: This multicenter, randomized, controlled, crossover trial of prepubertal
  children with cystic fibrosis (CF) tests the hypotheses that recombinant human GH
  (rhGH) treatment 1) improves height, weight, lean mass, and bone content irrespective
  of baseline measures; 2) improves clinical status and quality of life; and 3) has
  continued effect after cessation after 1 yr of treatment. METHODS: Sixty-one prepubertal
  subjects (<or=25th percentile for height and weight) were randomized into two groups:
  daily rhGH treatment or no treatment groups for 1 yr. In yr 2, treatments were crossed
  over. Outcome measures included serial standardized height and weight, number of
  hospitalizations and antibiotic courses, random blood glucose levels, lean mass,
  bone mineral content, pulmonary function, nutritional intake, and CF quality of
  life questionnaires. RESULTS: Groups were similar at baseline and prepubertal during
  the entire study. After 1 yr, GH showed significantly greater gain in height, weight,
  lean mass, and bone mineral content. Gain in height was similar regardless of baseline.
  There were fewer hospitalizations in the rhGH-treated group and improvement in CF
  quality of life questionnaires measures of weight and body image. There was no difference
  in pulmonary function between groups. Results were similar in those treated with
  rhGH the second year. After cessation of rhGH treatment, there was sustained effect
  for increased height and weight velocity, as well as accrual of bone mineral. CONCLUSION:
  rhGH therapy improves height and weight, decreases the number of hospitalizations,
  and improves quality of life in prepubertal children with CF. These effects are
  sustained after rhGH is discontinued.'
raw_completion_output: |-
  primary_disease: Cystic Fibrosis

  medical_actions: Growth hormone treatment; Hospitalizations; Antibiotic courses

  symptoms: Low height; Low weight; Decreased bone mineral content

  chemicals: Recombinant human GH (rhGH)

  action_annotation_relationships: Growth hormone treatment (with Recombinant human GH (rhGH)) TREATS Low height IN Cystic Fibrosis; Growth hormone treatment (with Recombinant human GH (rhGH)) TREATS Low weight IN Cystic Fibrosis; Growth hormone treatment (with Recombinant human GH (rhGH)) TREATS Decreased bone mineral content IN Cystic Fibrosis; Hospitalizations PREVENTS complications IN Cystic Fibrosis; Antibiotic courses PREVENTS infections IN Cystic Fibrosis
prompt: |+
  Split the following piece of text into fields in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Antibiotic courses PREVENTS infections IN Cystic Fibrosis

  ===

extracted_object:
  primary_disease: MONDO:0009061
  medical_actions:
    - Growth hormone treatment
    - Hospitalizations
    - Antibiotic courses
  symptoms:
    - Low height
    - HP:0004325
    - Decreased bone mineral content
  chemicals:
    - Recombinant human GH (rhGH)
  action_annotation_relationships:
    - subject: Growth hormone treatment
      predicate: TREATS
      object: Low height
      qualifier: MONDO:0009061
      subject_qualifier: with Recombinant human GH (rhGH)
      subject_extension: Recombinant human GH (rhGH)
    - subject: Growth hormone treatment
      predicate: TREATS
      object: HP:0004325
      qualifier: MONDO:0009061
      subject_qualifier: with Recombinant human GH (rhGH)
      subject_extension: Recombinant human GH (rhGH)
    - subject: Growth hormone treatment
      predicate: TREATS
      object: Decreased bone mineral content
      qualifier: MONDO:0009061
      subject_qualifier: with Recombinant human GH (rhGH)
      subject_extension: Recombinant human GH (rhGH)
    - subject: Hospitalizations
      predicate: PREVENTS
      object: complications
      qualifier: MONDO:0009061
    - subject: Antibiotic courses
      predicate: PREVENTS
      object: infections
      qualifier: MONDO:0009061
named_entities:
  - id: MONDO:0008891
    label: Brown-Vialetto-Van Laere syndrome
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: HP:0002093
    label: respiratory insufficiency
  - id: HP:0007141
    label: sensorimotor neuropathy
  - id: HP:0010871
    label: sensory ataxia
  - id: HP:0000365
    label: hearing loss
  - id: HP:0000648
    label: optic atrophy
  - id: CHEBI:17015
    label: riboflavin
  - id: HP:0012469
    label: infantile spasms
  - id: HP:0000789
    label: infertility
  - id: HP:0005268
    label: miscarriage
  - id: CHEBI:18405
    label: pyridoxal 5'-phosphate
  - id: CHEBI:16709
    label: pyridoxine
  - id: CHEBI:27306
    label: vitamin B6
  - id: CHEBI:24041
    label: flavin mononucleotide
  - id: MONDO:0015540
    label: Familial hemophagocytic lymphohistiocytosis (FHL)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:4911
    label: Etoposide
  - id: MAXO:0000757
    label: Infusion
  - id: MAXO:0000750
    label: Conditioning regimen
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: MONDO:0009666
    label: holocarboxylase synthetase deficiency
  - id: MAXO:0000603
    label: peritoneal dialysis
  - id: HP:0001942
    label: metabolic acidosis
  - id: CHEBI:15956
    label: biotin
  - id: MAXO:0009006
    label: Genome sequencing
  - id: MAXO:0000387
    label: Muscle biopsy
  - id: MAXO:0035059
    label: Nerve conduction studies
  - id: HP:0003701
    label: Proximal muscle weakness
  - id: HP:0002355
    label: Difficulty walking
  - id: HP:0002643
    label: Neonatal respiratory distress
  - id: CHEBI:8665
    label: Pyridostigmine
  - id: HP:0003256
    label: Coagulopathy
  - id: CHEBI:48669
    label: Tranexamic acid
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0020300
    label: Autosomal dominant nocturnal frontal lobe epilepsy
  - id: CHEBI:3387
    label: Carbamazepine
  - id: HP:0001250
    label: seizures
  - id: MONDO:0000903
    label: Myoclonus-dystonia
  - id: HP:0004308
    label: Ventricular arrhythmias
  - id: HP:0001645
    label: Sudden cardiac death
  - id: MAXO:0000943
    label: Deep brain stimulation
  - id: HP:0001252
    label: hypotonia
  - id: MAXO:0001082
    label: Trabeculectomy
  - id: MAXO:0000960
    label: Viscocanalostomy
  - id: HP:0007906
    label: Increased intraocular pressure
  - id: HP:0000253
    label: Progressive microcephaly
  - id: HP:0001263
    label: Global developmental delay
  - id: HP:0100785
    label: Insomnia
  - id: CHEBI:28892
    label: ganglioside
  - id: HP:0000252
    label: microcephaly
  - id: MAXO:0000950
    label: Supportive care
  - id: CHEBI:8378
    label: prednisolone
  - id: MONDO:0015626
    label: Charcot-Marie-Tooth disease (CMT)
  - id: MAXO:0035087
    label: Peripheral nerve biopsy
  - id: HP:0011096
    label: Demyelination
  - id: HP:0001605
    label: Vocal cord paralysis
  - id: HP:0003477
    label: Axonal neuropathy
  - id: MONDO:0007947
    label: Marfan's syndrome
  - id: HP:0001659
    label: aortic regurgitation
  - id: HP:0002647
    label: aortic dissection
  - id: CHEBI:6541
    label: losartan
  - id: CHEBI:2904
    label: atenolol
  - id: MONDO:0004691
    label: Autosomal dominant polycystic kidney disease (ADPKD)
  - id: HP:0002586
    label: Peritonitis
  - id: HP:0003774
    label: end-stage renal disease
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0003546
    label: exercise intolerance
  - id: HP:0001251
    label: ataxia
  - id: HP:0001332
    label: dystonia
  - id: HP:0001336
    label: myoclonus
  - id: HP:0001272
    label: cerebellar atrophy
  - id: HP:0002059
    label: cerebral atrophy
  - id: CHEBI:46245
    label: coenzyme Q10 (CoQ10)
  - id: MONDO:0009693
    label: Multiple myeloma
  - id: HP:0002720
    label: IgA deficiency
  - id: MONDO:0011787
    label: Limb-girdle muscular dystrophy type 2I (LGMD2I)
  - id: MONDO:0009662
    label: Sly disease (mucopolysaccharidosis VII)
  - id: HP:0040268
    label: recurrent infections of the middle ears
  - id: HP:0002321
    label: vertigo
  - id: HP:0002719
    label: recurrent infections
  - id: MONDO:0100137
    label: Telomere Diseases
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0001394
    label: Liver cirrhosis
  - id: HP:0002206
    label: Pulmonary fibrosis
  - id: HP:0003394
    label: Muscle cramps
  - id: CHEBI:4315
    label: Danazol
  - id: MONDO:0015286
    label: complete DiGeorge syndrome (cDGS)
  - id: MAXO:0010042
    label: thymus transplantation
  - id: HP:0001973
    label: autoimmune thrombocytopenia
  - id: HP:0100646
    label: thyroiditis
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:33281
    label: antimicrobials
  - id: MAXO:0035015
    label: visual acuity assessment
  - id: HP:0032341
    label: reduced Forced Vital Capacity
  - id: HP:0033482
    label: limited shoulder flexion
  - id: HP:0007663
    label: reduced visual acuity
  - id: HP:0012378
    label: fatigue
  - id: MONDO:0010421
    label: X-linked Agammaglobulinemia (XLA)
  - id: MONDO:0005180
    label: Parkinson disease
  - id: MONDO:0007765
    label: Hyperostosis cranialis interna
  - id: MONDO:0018997
    label: Noonan syndrome
  - id: MAXO:0000780
    label: hGH treatment
  - id: HP:0004322
    label: short stature
  - id: MONDO:0015168
    label: Arthrogryposis multiplex congenita
  - id: HP:0002828
    label: Multiple joint contractures
  - id: HP:0001558
    label: Reduced fetal movement
  - id: MONDO:0010518
    label: Wiskott-Aldrich syndrome
  - id: MAXO:0001077
    label: splenectomy
  - id: MONDO:0011724
    label: Glut-1 deficiency syndrome
  - id: HP:0005484
    label: acquired microcephaly
  - id: HP:0001257
    label: spasticity
  - id: HP:0011972
    label: hypoglycorrhachia
  - id: MONDO:0000188
    label: GLUT1 deficiency syndrome
  - id: HP:0001508
    label: Failure to thrive
  - id: HP:0000787
    label: Renal stones
  - id: CHEBI:37054
    label: 3-Hydroxybutyrate
  - id: MONDO:0019353
    label: Stargardt disease
  - id: MONDO:0015974
    label: Severe combined immune deficiency (SCID)
  - id: HP:0000964
    label: eczema
  - id: HP:0002960
    label: autoimmunity
  - id: HP:0001892
    label: hemorrhagic diathesis
  - id: MAXO:0000756
    label: transfusion
  - id: MONDO:0009561
    label: Alpha-mannosidosis
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: MAXO:0000011
    label: Physical therapy
  - id: MAXO:0000652
    label: Angiotensin-converting enzyme inhibitor therapy
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0010885
    label: Avascular necrosis
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: CHEBI:17334
    label: Penicillin
  - id: CHEBI:35457
    label: Angiotensin-converting enzyme inhibitors
  - id: HP:0001297
    label: stroke
  - id: CHEBI:35480
    label: analgesics
  - id: MONDO:0009061
    label: Cystic Fibrosis
  - id: HP:0004325
    label: Low weight
